Bafna Pharmaceuticals Q2 Results FY27: PAT Jumps 119.55% to Rs 6.85 Cr, Revenue Rs 47.67 Cr
- November 11, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Bafna Pharmaceuticals Q2 Results FY27 were declared on 11 November 2026 on a Standalone basis. Revenue for the July to September 2026 quarter rose 34.40% YoY to Rs 47.67 Cr from Rs 35.47 Cr. Net profit climbed 119.55% YoY to Rs 6.85 Cr from Rs 3.12 Cr. These quarterly results show strong YoY growth in both sales and profit.
Bafna Pharmaceuticals Ltd (BAFNAPH) Q2 Results FY27 announced on 11 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought Standalone figures with revenue of Rs 47.67 Cr and PAT of Rs 6.85 Cr. Bafna Pharmaceuticals Q2 Results FY27 show revenue 34.40% higher than last year, with net profit up 119.55% YoY, as the standalone results below confirm.
This results analysis covers the financial highlights, the business drivers, the outlook and the risks for the quarter. Readers who follow Bafna Pharmaceuticals Q2 Results on Univest can start with the summary table that comes next, and then move into the detailed reading.
Click Here – Get Free Investment Predictions
Bafna Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 47.67 Cr | Rs 35.47 Cr | +34.4% YoY |
| Operating Profit | Rs 8.6 Cr | Rs 4.28 Cr | +100.93% YoY |
| Net Profit (PAT) | Rs 6.85 Cr | Rs 3.12 Cr | +119.55% YoY |
Source: company filing for Bafna Pharmaceuticals Q2 Results FY27, 11 November 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Bafna Pharmaceuticals Q2 Results: What Stands Out
- Revenue: Rs 47.67 Cr against Rs 35.47 Cr a year earlier, a rise of 34.40% that marks strong YoY growth.
- Net profit: Rs 6.85 Cr compared with Rs 3.12 Cr in the year-ago quarter, an increase of 119.55% on a Standalone basis.
- Operating Profit: Rs 8.60 Cr versus Rs 4.28 Cr last year, a gain of 100.93% in Bafna Pharmaceuticals Q2 Results FY27.
- Margin: Net profit margin improved to 14.4% from 8.8% in the comparison quarter, alongside the higher profit lines.
- Risk headline: Quarterly net profit has been volatile over five quarters, so the next section reads the performance in detail.
Bafna Pharmaceuticals Q2 Results FY27: Performance Analysis
Bafna Pharmaceuticals reported Standalone revenue of Rs 47.67 Cr for July to September 2026, up from Rs 35.47 Cr, while Operating Profit rose 100.93% to Rs 8.60 Cr and net profit rose 119.55% to Rs 6.85 Cr. The quarter therefore pairs strong sales growth with profit that more than doubled.
In this results analysis, Bafna Pharmaceuticals Q2 Results FY27 show revenue growing by Rs 12.20 Cr over the year-ago quarter. That 34.40% YoY growth was followed by larger gains in profit, since Operating Profit moved from Rs 4.28 Cr to Rs 8.60 Cr and net profit moved from Rs 3.12 Cr to Rs 6.85 Cr.
Investors tracking Bafna Pharmaceuticals Q2 Results will look at later filings to see how revenue and profit settle against these levels. The quarterly results give a clear base for that comparison, which is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth of 34.4% – The results analysis points to revenue that grew 34.4% year on year to Rs 47.67 Cr in the latest quarter, which formed the base for the higher profit lines reported for the same period.
Net Profit Rise of 119.6% – Net profit rose 119.6% year on year to Rs 6.85 Cr. Bafna Pharmaceuticals Q2 Results FY27 therefore record profit growth well ahead of revenue growth, and the quarterly results show that gap clearly in the Financial Highlights table.
Improved Net Profit Margin – Net profit margin improved to 14.4% from 8.8% in the comparison quarter. This means a larger share of each rupee of revenue reached net profit, as the margin figures for the two quarters show.
FY27 Outlook After Bafna Pharmaceuticals Q2 Results
The full-year picture for FY27 will depend on the quarters that follow this one. Bafna Pharmaceuticals Q2 Results FY27 give the second quarter a reference point of Rs 47.67 Cr in revenue and Rs 6.85 Cr in net profit, and the next filings will show how those levels hold.
This results analysis does not rely on management guidance, because the article stays with the reported figures. Net profit of Rs 6.85 Cr, up from Rs 3.12 Cr, is the number later quarters will be compared with, and the Univest Screener tracks it, while the risks below frame what to watch.
Key Risks to Watch After Bafna Pharmaceuticals Q2 Results FY27
Volatile Quarterly Profit
Quarterly net profit has been volatile, ranging from Rs 0.08 Cr to Rs 6.85 Cr over the last 5 quarters. After Bafna Pharmaceuticals Q2 Results FY27, this wide range remains a reference point for investors reading the current profit level.
Return on Equity Below 15%
Return on equity of 12.27% in FY26 is below 15%. Strong YoY growth in quarterly profit does not change this earlier full-year figure, so investors will track how later quarters compare.
Debt Level
Debt was 0.39 times total assets in FY26. This balance sheet measure sits beside the current quarter and describes the earlier full-year position, so the conclusion draws the numbers together.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Bafna Pharmaceuticals Q2 Results FY27 show Standalone revenue of Rs 47.67 Cr, up 34.40% on last year, and net profit of Rs 6.85 Cr. These standalone results describe strong sales growth with faster profit growth, so the risks above still deserve attention. For investors following Bafna Pharmaceuticals Q2 Results, the quarterly results are best read alongside later filings and the Univest app. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Bafna Pharmaceuticals Q2 Results FY27
What are Bafna Pharmaceuticals Q2 Results FY27?
Ans. Bafna Pharmaceuticals Q2 Results FY27 cover the July to September 2026 quarter, with Standalone revenue of Rs 47.67 Cr and net profit of Rs 6.85 Cr, while the Quick Answer box gives the short summary.
What is the results date for Bafna Pharmaceuticals Q2 Results FY27?
Ans. The results were declared on 11 November 2026, so the results date for the July to September 2026 quarter is fixed, which means the opening sections of the article carry the same date.
What revenue was reported in Bafna Pharmaceuticals Q2 Results FY27?
Ans. Revenue was Rs 47.67 Cr for Bafna Pharmaceuticals in the quarter, compared with Rs 35.47 Cr a year earlier, as the Financial Highlights table shows alongside the other reported metrics.
What net profit was reported in Bafna Pharmaceuticals Q2 Results FY27?
Ans. Net profit was Rs 6.85 Cr in the quarter, compared with Rs 3.12 Cr a year earlier, which means the Key Takeaways section records an increase of 119.55%.
How much YoY growth did revenue show in Bafna Pharmaceuticals Q2 Results FY27?
Ans. Revenue showed YoY growth of 34.40%, rising from Rs 35.47 Cr to Rs 47.67 Cr, alongside faster profit growth that the Performance Analysis section describes in more detail.
Did net profit rise or fall in Bafna Pharmaceuticals Q2 Results?
Ans. Net profit rose 119.55% YoY, from Rs 3.12 Cr to Rs 6.85 Cr, and the Performance Analysis section places this rise beside the higher Operating Profit for the same quarter.
What was the Operating Profit in Bafna Pharmaceuticals Q2 Results FY27?
Ans. Operating Profit was Rs 8.60 Cr in the quarter, up 100.93% from Rs 4.28 Cr a year earlier, which is why the Performance Analysis section reads the profit lines together.
Are Bafna Pharmaceuticals Q2 Results consolidated results or standalone results?
Ans. Bafna Pharmaceuticals Q2 Results are Standalone results, so the figures reflect the company on its own, while the Financial Highlights table keeps the same basis for every metric shown for the quarter.
What business factors shaped Bafna Pharmaceuticals Q2 Results FY27?
Ans. The listed factors are revenue growth of 34.4% year on year, net profit growth of 119.6% and a net profit margin of 14.4% against 8.8%, as the Key Business Factors section explains.
What are the key risks after Bafna Pharmaceuticals Q2 Results FY27?
Ans. The risks are volatile quarterly net profit, return on equity of 12.27% and debt of 0.39 times total assets in FY26, as the Key Risks section sets out in detail.
What is the outlook after Bafna Pharmaceuticals Q2 Results?
Ans. The FY27 outlook depends on the quarters that follow, with Rs 6.85 Cr of net profit as the reference level, which means the Outlook section stays with reported figures only.
Where can I find the complete Bafna Pharmaceuticals Q2 Results FY27 data?
Ans. The complete data sits on the Univest Screener stock page, which lists the latest figures, while the Financial Highlights table in this article summarises the same quarter for quick reading.
